Solana Company (NASDAQ:HSDT) Short Interest Update

Solana Company (NASDAQ:HSDT) was the target of a significant decrease in short interest in February. As of February 27th, there was short interest totaling 1,010,452 shares, a decrease of 25.8% from the February 12th total of 1,361,910 shares. Approximately 3.0% of the shares of the company are sold short. Based on an average daily trading volume, of 369,148 shares, the days-to-cover ratio is currently 2.7 days. Based on an average daily trading volume, of 369,148 shares, the days-to-cover ratio is currently 2.7 days. Approximately 3.0% of the shares of the company are sold short.

Institutional Trading of Solana

Several institutional investors have recently made changes to their positions in HSDT. Price T Rowe Associates Inc. MD bought a new stake in Solana during the 4th quarter valued at approximately $46,000. Grant Private Wealth Management Inc bought a new position in Solana in the 4th quarter worth approximately $46,000. OMERS ADMINISTRATION Corp bought a new position in Solana in the 4th quarter worth approximately $88,000. Aristides Capital LLC purchased a new stake in Solana during the 4th quarter valued at approximately $137,000. Finally, XTX Topco Ltd purchased a new stake in Solana during the 4th quarter valued at approximately $140,000. Hedge funds and other institutional investors own 18.63% of the company’s stock.

Solana Stock Up 1.0%

HSDT stock traded up $0.02 during trading on Friday, reaching $2.11. The company’s stock had a trading volume of 131,457 shares, compared to its average volume of 393,746. Solana has a 1 year low of $1.74 and a 1 year high of $366.68. The company has a market capitalization of $87.14 million, a P/E ratio of 0.00 and a beta of 1.07. The company’s fifty day moving average is $2.53 and its 200-day moving average is $6.00.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on HSDT. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Solana in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of Solana from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Solana has an average rating of “Sell”.

Solana Company Profile

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.